Moreover, other studies have suggested that MUC1 may play a role in bortezomib resistance,21 and an anti‐MUC1 signal peptide vaccine has been explored in a Phase I/II study in multiple myeloma patients.22 The gene discussed is MUC1; the disease is plasma cell myeloma.